New antibiotic guidelines could save more lives in intensive care units

New antibiotic guidelines could save more lives in intensive care units

Antibiotic exposure and its priming effect on disease-causing bacteria UQ CCR Pharmacist Dr. Hafiz Abdul-Aziz worked with a team of experts to analyze data from 400 ICU patients and found one-third experienced adverse outcomes because their antibiotic therapy wasn't optimized to their needs. "We found a patient's response to the antibiotic improved significantly if the dosage was monitored and altered accordingly," Dr Abdul-Aziz said. The innovative guidelines were developed by 16 antibiotic experts from 11 different countries and recommended the use of advanced software to predict accurate drug dosages and generate personalized treatment regimens. Dr. Abdul-Aziz said more than 160,000 Australians required specialized care in ICU and 13 per cent of these patients died each year. ICU patients requiring antibiotics commonly suffer vital organ failure from sepsis, pneumonia or infections from burns. Dr. Abdul-Aziz said monitoring equipment and training needed to be rolled-out before routine TDM can be adopted as the worldwide standard-of-care. Source: University of Queensland Journal reference: Abdul-Aziz, M.H., et al . (2020) Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Medicine . doi.org/10.1007/s00134-020-06050-1 .



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More